CA
NZ
UK
AU
IND
US
Insmed’s latest 12-month data for its experimental pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP), revealed sustained efficacy and safety in an open-label extension study. The findings showed patients maintaining improvements in exercise capacity, biomarker levels, and functional status, reinforcing TPIP’s potential …
DePuy Synthes has bolstered its standing in the rapidly expanding spine surgery arena through the purchase of Expanding Innovations, aligning with Johnson & Johnson’s broader strategy to deepen its presence in high‑margin orthopaedic solutions. The X‑PAC TLIF and X‑PAC LLIF cages from Expanding Innovations …
Glaukos is facing fresh scrutiny from investors after an executive disclosed plans to offload 10,000 shares, a move that rippled through the eye-care sector and reignited concerns over margin compression. The sale, filed under Form 144 on 16 July, arrives as medical device manufacturers …
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) delivered a mixed quarterly update, posting record revenue for its narcolepsy drug WAKIX while missing earnings estimates and announcing the departure of its chief financial officer. The company reported preliminary Q2 net product revenue of approximately $261 million, …
Abbott Laboratories’ sharp upward revision to its 2026 profit outlook sent shockwaves through the healthcare sector, lifting its stock 14% to the highest level in three months. The move underscored growing confidence in the company’s ability to navigate supply chain pressures and pricing dynamics, …
Hims & Hers Health has become a focal point for options traders seeking dual profit opportunities as the stock’s technical strength solidifies. The telehealth company’s shares have established a clear uptrend, with price action forming successive higher lows and higher highs while maintaining support …
EnGene Therapeutics has appointed a new chairman to guide its board through a key regulatory phase, as the company advances toward a potential 2027 regulatory decision for its lead bladder cancer gene therapy. Michael Heffernan, a biopharmaceutical executive with extensive industry experience, assumed the …
The company’s shares responded instantly, rising more than ten percent to close at $98.81. This price action follows a year‑to‑date decline of roughly twenty percent, yet the stock has rallied over eleven percent in the past month. The market now values the company at …
Arbutus Biopharma (NASDAQ: ABUS) has formally ended a 2025 patent collaboration with Genevant Sciences that was linked to Moderna’s respiratory syncytial virus (RSV) vaccine program. This step follows a settlement with Moderna that delivered approximately $178 million to Arbutus, bringing closure to a series …
Cardiff Oncology has completed a $10.05 million stock offering, reinforcing its financial position as it navigates a challenging period for biotech stocks. The company sold 8,571,429 shares at $1.3125 per share, a price set above recent trading levels, alongside warrants that allow investors to …
Please wait processing your request...